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Photodynamic Therapy does not Prevent Cutaneous
Squamous-Cell Carcinoma in Organ-Transplant
Recipients: Results of a Randomized-Controlled Trial
Ymke G.L. de Graaf1, Cornelis Kennedy1, Ron Wolterbeek2, Annemie F.S. Collen1, Rein Willemze1
and Jan N. Bouwes Bavinck1
A randomized-controlled trial with paired observations was performed with 40 organ-transplant recipients to
assess the preventive effect of photodynamic therapy (PDT) on the development of new squamous-cell
carcinomas and to evaluate the effect of PDT on the number of keratotic skin lesions. The treatment area
consisted of a randomly assigned forearm and the corresponding hand, whereas the other forearm and hand
served as the control area. After the initial visit, follow-up visits were scheduled at 3-monthly intervals during 2
years. No statistically significant difference was found in the occurrence of new squamous-cell carcinomas
between the treated and untreated arms: after 2 years of follow-up, we observed 15 squamous-cell carcinomas
in nine out of 40 PDT-treated arms and 10 squamous-cell carcinomas in nine out of 40 control arms. The number
of keratotic skin lesions increased in both arms, but was less pronounced in the PDT-treated arm. After 1 year of
follow-up, a trend in favor of the PDT-treated arm was observed, but statistical significance was not reached.
Nearly 80% of the patients reported mild to severe adverse effects consisting of pain and a burning sensation,
immediately after the treatment. No long-term adverse events were noted. In conclusion, PDT does not appear
to prevent the occurrence of new squamous-cell carcinomas in organ-transplant recipients, but to some degree,
reduces the increase of keratotic skin lesions.
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INTRODUCTION
Skin carcinomas, especially squamous-cell carcinomas, that
develop on sun-exposed skin, are a serious hazard to organ-
transplant recipients (London et al., 1995; Euvrard et al.,
2003). The frequency of skin carcinomas increases progres-
sively with time after transplantation. In the Netherlands, the
risk to develop squamous-cell carcinoma increases up to
40%, 20 years after transplantation (Hartevelt et al., 1990).
The majority of organ-transplant recipients develop multi-
ple squamous-cell carcinomas, which appear to be more
aggressive in these patients in comparison with immuno-
competent individuals (Euvrard et al., 2003).
An association exists between squamous-cell carcinoma
and multiple keratotic skin lesions, and most lesions are
localized on sun-exposed skin such as the forearms and
dorsum of the hands (Bouwes Bavinck et al., 1993; Euvrard
et al., 2003).
Currently available therapies for skin carcinomas such as
excision and for solar keratoses such as topical application of
liquid nitrogen are less satisfactory for the treatment of large
affected areas, which is often the case in organ-transplant
recipients.
Prevention of squamous-cell carcinomas and reduction of
keratotic skin lesions with topical photodynamic therapy
(PDT) would, therefore, substantially improve the quality of
life of organ-transplant recipients.
PDT is a relatively safe procedure where a photosensitizer
is applied to the affected area and subsequently irradiated
with a light system. This treatment can be used to treat
superficial skin carcinomas or precancerous lesions that are
accessible to light (Morton et al., 2002). PDT involves the
activation of intracellular photosensitizers by visible light in
order to generate cytotoxic singlet oxygen and other free
radicals, which selectively destroy rapidly proliferating cells
(Hopper, 2000; Ormrod and Jarvis, 2000). As photosensiti-
zers, aminolevulinic acid (ALA) or methylaminolevulinic acid
are used (Morton et al., 2002).
PDT with topical ALA is a safe and effective treatment for
solar keratoses (Ormrod and Jarvis, 2000; Brown et al., 2004).
The efficacy has been demonstrated for non-hyperkeratotic
solar keratoses on the face or scalp of immunocompetent
individuals. Response rates were comparable with cryother-
apy and 5-fluorouracil, but a better cosmetic result was
See related commentary on page 542
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reached (Morton et al., 2002). Furthermore, Bowen’s disease
and superficial basal-cell carcinomas can also be effectively
treated with PDT (Varma et al., 2001; Kormeili et al., 2004).
PDT has also been shown to be effective in treating
recalcitrant viral warts (Stender et al., 2000; Ibbotson, 2002).
Only two studies concerning the efficacy of PDT in
immunosuppressed patients are available. Although lower
cure rates are reported in organ-transplant recipients com-
pared to the immunocompetent controls (Dragieva et al.,
2004a), both studies report a good efficacy of PDT for solar
keratoses in organ-transplant recipients (Dragieva et al.,
2004a, b). In addition, experimental studies in hairless mice
have shown that PDT can delay the development of UV-
induced skin carcinomas (Stender et al., 1997; Sharfaei et al.,
2002).
The primary objective of this trial was to assess the
occurrence of new squamous-cell carcinomas in organ-
transplant recipients in the treated arm compared with the
control arm following PDT. A second objective was to
evaluate the difference in (re)occurrence of keratotic skin
lesions in the arm treated with PDT compared to the control
arm. Finally, we studied the difference in efficacy between a
regimen with one PDT treatment or two PDT treatments with
a 6-month period in between the treatments.
RESULTS
A total of 45 patients gave informed consent. Forty of them
were randomized two-fold: 21 to receive PDT to the left
forearm and hand, 19 to receive PDT to the right forearm and
hand and 23 patients were randomized to one PDT treatment
(at T0) and 17 to two PDT treatments (at T0 and T6). The
other five patients had been included previously in the non-
randomized pilot part of the study and they received only one
PDT treatment (at T0).
The characteristics of the patients are listed in Table 1.
During the 2-year follow-up period, seven patients were lost
to follow-up. Five patients died from another cause then skin
cancer after 3 months (two patients), and after 9, 12, and 21
months, respectively. Two patients were lost to follow-up
after 18 and 24 months, respectively, without any apparent
reason. The characteristics of the treated and control arm at
the start of the trial are depicted in Table 2.
During the 2-year follow-up period, a total of 25
squamous-cell carcinomas and no other types of skin cancer
were detected on the forearms and hands of the 40 patients in
the randomized part of the trial. Figure 1b shows the
distribution of the clinical outcome among these patients.
In six patients one squamous-cell carcinoma developed in the
control arm and none in the PDT-treated arm, and in one
patient two squamous-cell carcinomas developed in the
control arm and none in the PDT-treated arm. By contrast, in
six patients one squamous-cell carcinoma developed in the
PDT-treated arm and none in the control arm, in one patient
three squamous-cell carcinomas developed in the PDT-
treated arm and none in the control arm, and in one patient
five squamous-cell carcinomas developed in the PDT-treated
arm and one in the control arm. In one patient one
squamous-cell carcinoma developed in the PDT-treated
Table 1. Characteristics of the patients
Randomized
trial Pilot trial
No. of patients 40 5
Sex
Male 21 2
Female 19 3
Age (years)
Mean7SD 55.078.8 58.076.9
Range 39–71 50–68
Immunosuppressive treatment
Prednisone and azathioprine 37 5
Prednisone and cyclosporine 1 0
Prednisone, azathioprine, and
cyclosporine
2 0
Time after transplantation (years)
Mean7SD 22.076.3 17.973.3
Range 7–34 12–21
History of SCC anywhere on the body
No. of patients with SCC (%) 31 (78) 4 (80)
Mean no. of SCC7SD 8.279.9 6.876.5
Range 0–42 0–17
SCC: squamous-cell carcinoma; SD: standard deviation.
Table 2. Characteristics of the PDT-treated and the
control arm and hand at the start of the trial
PDT-treated
arm Control arm
Randomized part of the trial
No. of arms 40 40
Side of the arm
Left 19 21
Right 21 19
History of SCC per arm
No. of arms with SCC (%) 18 (45) 19 (48)
Mean no. of SCC7SD 1.071.3 1.171.7
Range 0–4 0–8
No. of keratotic lesions per arm
Mean7SD 31722 27719
Range 9–96 6–103
Pilot part of the trial
No. of arms 5 5
Side of the arm
Left 2 3
Right 3 2
History of SCC per arm
No. of arms with SCC (%) 2 (40) 2 (40)
Mean no. of SCC7SD 0.670.9 0.470.5
Range 0–2 0–1
SCC: squamous-cell carcinoma; SD: standard deviation.
570 Journal of Investigative Dermatology (2006), Volume 126
YGL de Graaf et al.
PTD and Squamous-Cell Carcinoma
arm and one in the control arm and in 24 patients no
squamous-cell carcinomas developed in any arm. Altogether,
15 squamous-cell carcinomas developed in nine out of 40
PDT-treated arms and 10 squamous-cell carcinomas in nine
out of 40 control arms.
In the pilot study, four squamous-cell carcinomas devel-
oped in two out of five patients: one in the PDT-treated arm
and three in the control arm. One patient developed one
squamous-cell carcinoma in the control arm and none in the
PDT-treated arm and one patient developed two squamous-
cell carcinomas in the control arm and one in the PDT-
treated arm.
The occurrence of new squamous-cell carcinomas was not
statistically significantly different between the PDT-treated
arm and the control arm within the 2-year follow-up period
neither in the randomized part of the study (P¼ 0.80) nor in
the pilot study (P¼ 0.16) and also not when the outcomes of
both studies were combined (P¼ 0.81). One or two PDT
treatments did not influence the outcome of squamous-cell
carcinoma significantly (data not shown).
Figure 2 depicts the distribution and mean number of
keratotic skin lesions in the control arms (panel a) and in the
PDT-treated arms (panels b–d). Panel b shows the distribution
and mean number of keratotic skin lesions of all PDT-treated
arms, irrespective of whether they were treated one time or
two times, panel c shows the arms that received one PDT
treatment only, and panel d shows the arms that received two
PDT treatments only.
Unexpectedly, at the start of the study, we found a relevant
difference between the number of keratotic skin lesions in the
arms randomized to be treated with PDT and the control arm
with a mean of 4.5 more keratotic skin lesions in the arms
that were randomly selected to be treated with PDT (Figure
2e). For this reason, all time points were compared with
baseline (T0) as depicted in Figure 2f.
Planned pairwise comparison on the basis of a linear
mixed model approach focused on the comparison between
time points T3, T6, T9, and T12 versus T0 resulted in a
statistically significant difference at time points T9 and T12
(Figure 2f). The overall fixed effect of time, however, was not
statistically significant (P¼ 0.06).
Two PDT treatments appeared to reduce the increase of
keratotic skin lesions at time points T9 and T12 slightly more
than one PDT treatment (Figure 2c and d), but using a
summary measure approach based on Wilcoxon’s rank-sum
test on regression slopes from simple linear regression of
individual patients, the difference in the median values of the
regression slopes was not statistically significant (P¼0.39).
In total, 79% of patients reported adverse effects during
PDT treatment or in the first week after treatment. Most
prevalent were a burning sensation (38%) and pain (31%).
A minority of patients reported itch (9%) and blisters (2%). No
long-term adverse effects were reported. There were no
withdrawals of the patients because of adverse effects.
DISCUSSION
PDT, using topical d-ALA and violet light (400–450 nm)
applied to the forearm and corresponding dorsum of the
hand, did not significantly prevent the development of new
squamous-cell carcinomas in organ-transplant recipients
within a 2-year follow-up period. The PDT procedure,
however, to some extent, diminished the increase of keratotic
skin lesions in the PDT-treated arm and hand compared to
the nontreated control area, but at the expense of pain and
irritation during and shortly after the procedure.
Generally, the forearms and dorsum of the hands of organ-
transplant recipients have undergone a field change, meaning
that the skin in this area shows histological atypia (Berg and
Otley, 2002). This may be clinically visible by the presence of
numerous premalignant actinic keratoses and other keratotic
skin lesions and results in an increased risk to develop
squamous-cell carcinomas in this area of the skin. Hypo-
thetically, treating the whole area with PDT and thus
selectively destroying the premalignant cells should result
in a reduced risk of squamous-cell carcinoma. Unfortunately,
such an effect was not observed in this randomized-
controlled trial.
A possible explanation that we did not observe a
preventive effect of the PDT procedure on the development
of new squamous-cell carcinomas may be that the follow-up
period of 2 years was too short. However, after 2 years of
follow-up, nine out of 40 patients (22.5%) developed new
squamous-cell carcinomas in the control arm, which is close
to the approximately 25% of patients who were expected to
develop new squamous-cell carcinomas in the control arm
during the 2-year follow-up period. In addition, 23 out of 40
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Figure 1. Expected and observed number of patients after 2 years of follow-
up. (a) Expected number of patients with 95% confidence intervals based on
the assumption that after a 2-year follow-up period, 5% of the PDT-treated
arms and 25% of the control arms would develop one or more squamous-cell
carcinomas. The numbers are provided for a total of 40 patients (80 arms).
(b) Observed number of patients with squamous-cell carcinoma with 95%
confidence intervals after a 2-year follow-up period, showing that the control
arm was better than the PDT-treated arm in eight (20%) of the 40 patients and
the PDT-treated arm was better in seven (17.5%) of the 40 patients.
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patients (57.5%) had developed a total of 84 squamous-cell
carcinomas on the rest of the body during the 2-year follow-
up period (data not shown), indicating that a 2-year follow-up
period should be sufficient to harbor enough squamous-cell
carcinoma events in the PDT-treated arm and the control
arm. If the PDT procedure had been effective, a significantly
lower occurrence of squamous-cell carcinoma would have
been observed in the PDT-treated arm, which, obviously, was
not the case.
Another possible explanation that the PDT procedure was
not effective may be the selection of the patients. We selected
patients who needed intervention the most, that is, patients
who often had a history of one or more squamous-cell
carcinomas and at least 10 hyperkeratotic skin lesions present
on the forearms and dorsum of the hands. This selection is illu-
strated by the fact that the time period since transplantation
ranged between 7 and 34 years. We cannot exclude that PDT
intervention at an earlier time period after transplantation,
at an earlier stage of skin cancer development, may be more
effective.
Still another possible explanation that the PDT procedure
was not successful in our hands may be the character of the
light source and the photosensitizer that we used. Red light
(570–750 nm) is often used as the light source for PDT
because of the greater depth of penetration. We used violet
light (400–450 nm) because violet light has a maximum
overlap with the excitation spectrum of protoporphyrin IX,
and, therefore less light energy is required for the same effect
(Dijkstra et al., 2001). As photosensitizer we used d-ALA.
Methylaminolevulinic acid, the methyl ester of ALA, has the
advantage of penetrating deeper into the skin, and possibly
could result in a better therapeutic result.
Additionally, we did not pretreat the keratotic skin lesions
with curettage, because this was not feasible considering the
large amount of keratotic skin lesions in our patients. As a
result, thick keratotic skin lesions were possibly not optimally
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Figure 2. Distribution and mean number of keratotic skin lesions at the start of the trial and at 3-monthly intervals (a) in the control arm, (b) in the
PDT-treated arm, irrespective of one or two treatments, (c) with one treatment only, and (d) with two treatments only. (e) Uncorrected difference between
the number of keratotic skin lesions in the PDT-treated arm and the control arm and (f) difference corrected for the difference at the start of the trial are shown.
The bars indicate 95% confidence intervals.
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treated with PDT, because of insufficient penetration of the
photosensitizer in these lesions. Inferior response to PDT of
thick keratotic skin lesions on the hands compared to the
thinner lesions on the face has been demonstrated in
immunocompetent patients (Morton et al., 2002), and in
immunocompromised patients it is probably even more
difficult to treat these keratotic skin lesions with PDT
(Dragieva et al., 2004a).
Still another explanation that the PDT procedure may not
have been successful may be that the favorable effect of PDT
was counterbalanced by a harmful effect of the violet light
source we used, but data to substantiate this suggestion are
not available.
Whereas the occurrence of new squamous-cell carcino-
mas is a solid end point of this study, the number of keratotic
skin lesions is a much weaker end point. Counting keratotic
skin lesions is difficult to standardize; observers tend to
improve their counting scales during time, and intra-observer
and inter-observer variation may be significant. The advan-
tage of paired analyses is that intra-observer variation is
minimized and variation during time is reduced, because
inaccurate counting should equally affect both the treated
and control arms in all patients. Despite the methodological
limitations, a trend to reduction of the increase of keratotic
skin lesions in the PDT-treated arm and hand compared to
the nontreated control area was observed. With a more
accurate measurement of keratotic skin lesions, this effect is
likely to be more discernible and would possibly reach
statistical significance.
In summary, PDT using topical d-ALA with a violet light
source (400–450 nm) does not appear to prevent the
development of new squamous-cell carcinomas in organ-
transplant recipients. PDT has also no significant effect
on the reduction of keratotic skin lesions although a trend
in favor of the PDT-treated arm was observed. A possible
positive effect of PDT, however, goes at the expense of
significant short-term side effects, and, therefore, PDT
performed with topical d-ALA and violet light does not
appear to be a promising preventive therapy in organ-
transplant recipients.
MATERIALS AND METHODS
Eligible patients
Organ-transplant recipients who were regularly evaluated at the
Department of Dermatology and/or Nephrology from the Leiden
University Medical Center in the period between August 2000 and
February 2003 were eligible to participate in the trial.
Inclusion criteria were a history of skin carcinoma and/or at least
10 keratotic skin lesions present on both forearms and hands at the
day of inclusion; an age of 18 years or older; and a functioning graft
of 5 years or longer.
Keratotic skin lesions consisted of solar keratoses, flat warts,
seborheic warts, and common warts. Because it is difficult to
discriminate these different keratotic skin lesions on clinical and
histological grounds, they were considered together. Patients who
presented with a skin carcinoma at the start of the trial were only
included after excision of the skin cancer, which needed to be fully
healed before topical application with the photosensitizer. Patients
who were using acitretin and women with childbearing potential
were excluded from the study.
The medical ethical committee of the Leiden University Medical
Center approved the study, and all participants provided written
informed consent. The study adheres to the Declaration of
Helsinki Principles and was approved by the local medical ethics
commission.
Study design
A randomized-controlled trial with a self-controlled design, consist-
ing of a right/left comparison was performed. One forearm and the
corresponding hand were randomly allocated to the PDT procedure,
and the other forearm and hand served as the control area and
remained untreated. In addition, patients were randomly allocated to
one or two PDT procedures. The first group received only one
treatment at the start of the trial (T0), whereas the second group
received a second PDT procedure 6 months later (T6).
The clinical pharmacy from our hospital performed the rando-
mization procedure. A computer program automatically generated a
randomization list with a study number and the patients were
randomized accordingly. Owing to the nature of the treatment,
blinding of the patients was not possible. The physician, however,
was blinded for the treatment arm at the follow-up visits and the
patients were requested not to inform the physician which arm had
been treated. Follow-up visits were scheduled every 3 months during
2 years. At the start of the trial and at each follow-up visit, the skin of
both forearms and hands was checked for the presence of squamous-
cell carcinomas and any other possible type of skin cancer. All
newly suspected lesions were evaluated histologically. Only
histologically confirmed squamous-cell carcinomas were included
in the study. A follow-up time of 24 months was completed to
evaluate the occurrence of new squamous-cell carcinomas. The
numbers of keratotic skin lesions on both forearms and correspond-
ing hands were counted during a follow-up time of 12 months. To
minimize inter-observer variation, the same physician evaluated
each patient at all visits, with few exceptions.
The randomized-controlled trial had been preceded by an open
non-randomized-pilot phase with five different organ-transplant
recipients to optimize the PDT procedure itself. The same inclusion
and exclusion criteria had been applied to the pilot study as for the
later randomized-controlled trial. In the pilot study, only new skin
cancers were evaluated during follow-up.
PDT treatment
The PDT treatment was adapted from a protocol used by our
colleagues in Utrecht, The Netherlands (Dijkstra et al., 2001). The
clinical pharmacy from our hospital freshly produced the ALA
formulation for each patient visit. Patients received topical cream
containing 200 mg d-ALA HCl per 1 g of Lanette cream base on the
randomly allocated forearm and hand. After application of the
cream, the forearm and hand were covered with a Tegaderm
dressing, which was applied for a duration of 4 hours. The dressing
was removed shortly before the irradiation procedure. The light
source we used produced a wavelength band of 400–450 nm (Philips
HPM-10, 400 W) (Dijkstra et al., 2001). The duration of the
irradiation procedure was 17 minutes, resulting in a total light dose
of 5.5–6 J/cm2. The patients were instructed to cover the treated arm
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and hand after the PDT procedure for the rest of the day to avoid
extra irradiation.
We decided not to pretreat the keratotic skin lesions with
curettage, because this was not feasible considering the large
amount of keratotic skin lesions in our patients. Other ‘‘field’’
treatments, such as 5-fluorouracil or imiquimod cream, were not
allowed during the 2-year post-treatment period.
Statistical analysis
The sample size was calculated based on the findings of a previous
double-blind placebo-controlled study assessing the efficacy of
acitretin in the prevention of new squamous-cell carcinomas
(Bouwes Bavinck et al., 1995). We had observed that in the placebo
group within a 6-month period, nine out of 19 patients had
developed altogether 15 new squamous-cell carcinomas anywhere
on the body.
Based on these findings, it was expected that, within a 2-year
follow-up period, at least 50% of the organ-transplant recipients
would develop one or more squamous-cell carcinomas on both
forearms or hands (25% per arm and hand). In order to have an
effective preventive treatment, we stipulated that only 5% of the
treated arms were allowed to develop new squamous-cell carcino-
mas compared to 25% in the control arm during the same 2-year
follow-up period. With a power of 90% and a significance level of
0.05, we calculated that 45 patients would be sufficient to
distinguish significantly between a skin cancer occurrence (at the
2-year follow-up) of 5% in the treated arm and 25% in the untreated
arm (Figure 1a).
For the statistical analyses, we used SPSS version 12.0.1 for
Windows. The difference regarding the number of new squamous-
cell carcinomas between the PDT-treated and the control arm was
calculated with a Wilcoxon’s signed rank test.
For the effect of the PDT treatment on the number of keratotic
skin lesions, we used a linear mixed model approach with fixed time
effects for repeated measurements based on the differences in the
number of keratotic skin lesions between the PDT-treated arm and
hand and the control arm and hand at different time points. We used
a summary measure approach based on Wilcoxon’s rank-sum test on
regression slopes from simple linear regression of individual patients
to assess whether there was a difference in the time course of change
of number of lesions for arms and hands receiving one or two PDT
treatments after 9 (T9) and 12 months (T12) of follow-up.
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